-
LDH Cytotoxicity Assay Kit: Workflow & QC
2026-08-31
The LDH Cytotoxicity Assay Kit (SKU K2228) provides a non-radioactive colorimetric approach for cell cytotoxicity measurement by detecting LDH released into culture medium after membrane damage. It is intended for comparative in vitro studies, not for assigning a specific death pathway, in vivo testing, or clinical diagnosis.
-
Dabigatran Etexilate: Oral Thrombin Inhibition
2026-08-31
This clinical review examines dabigatran etexilate as the first oral direct thrombin inhibitor marketed in the United States, emphasizing its rapid, predictable anticoagulant activity and reduced dependence on INR monitoring. Its prodrug conversion, renal clearance, efficacy across thromboembolic settings, and bleeding-related limitations remain central to interpreting its clinical role.
-
Humanized Mice Clarify HD56 Prodrug Exposure
2026-08-30
The 2025 reference study shows that humanized-liver mice can resolve species-dependent metabolism of the CES-activated prodrug HD56 and improve prediction of its conversion to HD561. Its strong in vivo–in vitro correlation highlights why human-relevant metabolic models are valuable when conventional animal data are difficult to translate.
-
Graphene-Induced Apoptosis in Melanoma Cells
2026-08-29
The reference study shows that graphene film suppresses B16F10 melanoma-cell proliferation while engaging intrinsic apoptosis, oxidative stress, and G0/G1 cell-cycle arrest. Its combination of transcriptomics, biochemical readouts, and caspase-inhibitor rescue experiments provides a useful framework for interpreting how nanomaterial exposure reshapes melanoma cell-death programs.
-
RHEB Neddylation Links UBE2F to Liver Tumorigenesis
2026-08-28
The reference study identifies RHEB as a non-cullin substrate of the UBE2F-SAG neddylation machinery and maps the functionally important modification to K169. By connecting this modification with lysosomal RHEB localization, GTP binding, mTORC1 activation, and PTEN-loss-driven liver tumorigenesis, the work establishes a mechanistic link between neddylation and oncogenic nutrient signaling.
-
CGRP/SP–Piezo2 Axis in Trigeminal Neuralgia
2026-08-28
Liao et al. identify a Ca2+-dependent CGRP/SP–Piezo2 positive-feedback loop linking trigeminal root compression, neuroinflammation, and mechanical allodynia. Their rat and in vitro experiments place PKC, cAMP, extracellular ATP, ERK1/2, and p38 MAPK within a compartment-specific TG neuron–Merkel cell mechanism that may clarify how touch becomes painful in trigeminal neuralgia.
-
HSP90 Inhibition Rewires Lung Adenocarcinoma Proteomes
2026-08-27
This study used two-dimensional electrophoresis and mass spectrometry to map how pharmacological HSP90 disruption changes the proteome of lung adenocarcinoma cells. Its identification of 254 differentially expressed proteins, including eIF3i and citrate synthase, connects chaperone inhibition with apoptosis, serine-glycine metabolism, and the tricarboxylic acid cycle while providing candidate response biomarkers.
-
FLAG tag Peptide: Assay Design for NMD Biology
2026-08-27
Discover how the FLAG tag Peptide and DYKDDDDK peptide support controlled recombinant protein detection, purification, and mechanistic studies of the Smg5–Hnrnpl–Mag axis. This guide focuses on assay architecture, interpretation, and limitations rather than a conventional product overview.
-
Tetrazolium (chloride) for Viability Assays
2026-08-26
Tetrazolium (chloride), also called Tetrazolium Red or TTC, converts mitochondrial dehydrogenase activity into a visible red formazan signal for cell and tissue analysis. Its combination of spectrophotometric quantification and spatial staining makes it especially useful for ischemic injury research, including stroke and cardiac infarction models.
-
Bufuralol in Human Intestinal Organoid Pharmacology
2026-08-26
Bufuralol hydrochloride offers translational researchers more than a conventional beta-blocker control. Its non-selective receptor profile, partial intrinsic sympathomimetic activity, and established cardiovascular pharmacology relevance can be evaluated alongside human induced pluripotent stem cell-derived intestinal organoids to connect oral exposure, metabolism, transporter activity, and cardiovascular pharmacodynamics.
-
Quercetin in LPS-Induced Depression: NLRP3 Findings
2026-08-25
A 2026 pre-proof study examined Quercetin in an LPS-induced mouse model of depression and linked behavioral improvement to reduced hippocampal NLRP3-associated inflammation. Its combined mood, cognition, microglial, and cytokine readouts support Quercetin as an anti-inflammatory agent for mechanistic antidepressant research, while leaving pathway causality and clinical translation unresolved.
-
SR 11302: Translating AP-1 Blockade to Oncology
2026-08-25
SR 11302 is a retinoid-independent AP-1 transcription factor inhibitor that connects tumor-cell biology, chemoprevention, and immune-context research. This thought-leadership analysis explains how to use AP-1 blockade as a translational decision tool while interpreting macrophage-polarization evidence without overstating the current data.
-
Chlorpromazine Workflows for Receptor & Nanoparticle Studies
2026-08-24
Build reproducible dopamine receptor signaling assays with chlorpromazine hydrochloride while using the same compound as a carefully controlled pharmacological perturbation in translational nanomedicine workflows. This guide connects antipsychotic research with cell-resolved hepatic nanoparticle studies without overstating what the current evidence proves.
-
PID1, Oxysterols, and Antitumor Macrophage Immunity
2026-08-24
The reference study identifies PID1 as an immunometabolic regulator that shapes tumor-associated macrophage fate through LDL uptake, cholesterol accumulation, ROS production, and oxysterol generation. Its findings connect 5α,6α-epoxycholesterol and 7β-hydroxycholesterol with suppression of mTOR–STAT6 signaling, reduced ARG1 expression, and stronger CD8+ T cell-mediated tumor surveillance.
-
(S)-(+)-Ibuprofen COX Inhibitor Guide
2026-08-23
Build more controlled inflammation and pain assays with the pharmacologically active ibuprofen enantiomer, using solvent-aware dosing and orthogonal biological readouts. The same workflow can be extended cautiously to aquatic toxicology, where exposure verification and biodegradation controls are essential.